Income Statement
CULLINAN THERAPEUTICS, INC.
CGEM
Performance Overview
Click any row in the table to add it to this chart
in millions USD
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY | Dec 31, 2022 2022 FY | Dec 31, 2021 2021 FY |
|---|---|---|---|---|---|
|
Revenue
|
- | - | - | 0.00 | 18.94 |
|
Cost of Revenue
|
- | - | - | - | - |
|
Gross Profit
|
- | - | - | - | 18.94 |
|
Operating Expenses
|
241.65 | 196.92 | 190.65 | 132.14 | 86.90 |
|
Research & Development
|
187.40 | 142.90 | 148.16 | 91.95 | 57.75 |
|
Selling, General & Administrative
|
54.25 | 54.02 | 42.49 | 40.19 | 29.15 |
|
Other Operating Expenses
|
- | - | - | - | - |
|
Operating Income
|
-241.65 | -196.92 | -190.65 | -132.14 | -67.95 |
|
Non-Operating Income
|
-21.77 | -29.46 | -21.43 | -283.45 | - |
|
Interest Income
|
22.21 | 29.66 | 21.63 | 6.61 | 0.48 |
|
Interest Expense
|
- | - | - | - | - |
|
Other Non-Op Income / Expense
|
-0.44 | -0.20 | 0.24 | 0.06 | -0.01 |
|
Income Before Tax
|
-219.88 | -167.46 | -169.22 | 151.32 | - |
|
Income Tax Expense
|
0.00 | -0.08 | -16.06 | 40.10 | - |
|
Non-Controlling Interest
|
0.00 | 4.40 | -1.94 | 1.20 | 5.40 |
|
Net Income
|
-219.88 | -167.38 | -153.16 | 111.21 | -65.57 |
Supplemental
Per share data, derived & other items — not part of the income statement
in millions USD unless noted
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY | Dec 31, 2022 2022 FY | Dec 31, 2021 2021 FY |
|---|---|---|---|---|---|
|
Depreciation & Amortization
|
- | - | - | - | - |
|
EBITDA
|
-241.34 | -196.61 | -190.34 | -132.04 | -67.90 |
|
Earnings Per Share (Basic)
|
-3.36 | -2.78 | -3.69 | 2.46 | - |
|
Diluted EPS
|
-3.36 | -2.78 | -3.69 | 2.38 | - |
|
Weighted Average Shares
|
59.05 | 53.77 | 41.55 | 45.16 | - |
|
Diluted Weighted Avg Shares
|
59.05 | 53.77 | 41.55 | 46.64 | - |
|
Comprehensive Income
|
-218.73 | -167.39 | -150.69 | 109.45 | -66.41 |